Genetics News

SAN DIEGO--(BUSINESS WIRE)--Today, Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, announced MRDVision, its solution for minimal residual disease (MRD) detection, validated to CLIA standards. The assay, previously available for research use only, is now ready for use in clinical settings, redefining the standard in MRD testing by enabling ultra-sensitive detection of circulating tumor DNA (ctDNA) with a simulated limit of detection (LOD) as low as 1 part per million (ppm)...

DUBLIN--(BUSINESS WIRE)--The "Genetic Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offering. The global genetic testing market is projected to reach an impressive valuation of US$ 49.72 billion by 2033, up from US$ 21.47 billion in 2024, exhibiting a CAGR of 9.78% between 2025 and 2033. This growth trajectory is driven by advancements in technology, burgeoning demand for personalized medicine, and an increased p...

LOS ANGELES--(BUSINESS WIRE)--A team led by Children's Hospital Los Angeles (CHLA) has become the first in the world to demonstrate the possibility of using genetically engineered pig hearts as a potential “bridge” to heart transplant for critically ill babies. The groundbreaking preclinical research could lead to a lifesaving alternative for supporting critically ill babies waiting for a new heart—particularly those with single-ventricle heart disease, most of whom currently die while waiting...

PALO ALTO, Calif.--(BUSINESS WIRE)--Throughout release, "exome-wide" should read as "genome-wide". The updated release reads: GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer genome-wi...

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics achieves milestone for in vivo program in collaboration with Prevail Therapeutics, and announces ASGCT joint presentation...

DUBLIN--(BUSINESS WIRE)--The "KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The global market for KRAS inhibitors has seen substantial growth in recent years, largely due to the heightened awareness of KRAS mutations as significant contributors to cancer development in various solid tumors, including lung, colorectal, and pancreatic cancers. KRAS, an essential gene that regulates cell proliferati...

GLENVIEW, Ill.--(BUSINESS WIRE)--Asahi Kasei Bioprocess America, Inc. (AKBA) has been recognized with the Best Technologies Innovation Award at INTERPHEX 2025....

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced positive long-term results from its QUILT-3.032 study of ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary disease. The findings were shared during an oral presentation at the American Urological...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a debilitating, rapidly...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Conference: The Citizens Life Sciences Conference Date: Wednesday,...